Exchange Traded Concepts LLC Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Exchange Traded Concepts LLC lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 45.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 3,352 shares of the biopharmaceutical company's stock after selling 2,807 shares during the period. Exchange Traded Concepts LLC's holdings in Regeneron Pharmaceuticals were worth $2,126,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $25,000. OFI Invest Asset Management purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. Tompkins Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $32,000. Finally, Curat Global LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

REGN has been the subject of a number of analyst reports. Morgan Stanley lowered their price target on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a research report on Monday, June 2nd. Bank of America lowered their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. Robert W. Baird cut their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. UBS Group decreased their price objective on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating for the company in a research note on Thursday, June 5th. Finally, The Goldman Sachs Group dropped their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $836.48.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded up $4.72 during mid-day trading on Wednesday, hitting $513.58. The stock had a trading volume of 841,026 shares, compared to its average volume of 882,745. The firm has a market cap of $55.45 billion, a PE ratio of 13.07, a PEG ratio of 1.91 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The company has a 50 day moving average of $561.15 and a two-hundred day moving average of $645.97. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the prior year, the company posted $9.55 earnings per share. The firm's revenue for the quarter was down 3.7% on a year-over-year basis. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.